Objective: Hot flashes are valuable indicators of physiological condition and drug effect; however, subjective and objective measures do not always agree. No study has examined both subjective and objective hot flashes in women prescribed aromatase inhibitors. The study (1) compared subjective and objective hot flash measures, (2) examined changes in subjective and objective hot flashes over time, and (3) evaluated predictors of change in hot flashes in aromatase inhibitorYtreated women.
H ot flashes are the cardinal symptom of menopause and are important indicators of physiological condition and of drug effect. Hot flashes can be measured subjectively via self-report and objectively via sternal skin conductance monitoring. Data from American and international populations show that subjective and objective measures do not always agree. 1<5 During daytime and in a laboratory setting, concordance between subjective and objective monitoring has been reported to be near 100%. 6 However, concordance between objective and subjective hot flashes is low in nighttime laboratory studies 5 and in daytime or nighttime ambulatory studies. 1 Women may report hot flashes that do not register objectively or may not report hot flashes that do register objectively.
Although it is possible that women may overreport hot flashes to qualify for a treatment study, our previous data from breast cancer survivors indicated that this was not true. Breast cancer survivors seeking treatment for hot flashes tended to underreport hot flashes meeting objective criteria. 1, 7 Compared with monitor-detected hot flashes, subjective hot flash reports such as paper diaries and electronic event buttons significantly underestimated hot flashes in breast cancer survivors seeking treatment for the symptom. Using at-home objective monitoring, breast cancer survivors underreported 50% to 64% of daytime objective hot flashes and 58% to 78% of nighttime objective hot flashes. 1, 7 In another study of breast cancer survivors, women reported difficulty completing hot flash diaries because of sleep, being too busy, or other reasons. 1, 7 No published studies using both objective and subjective methods have examined changes in hot flashes related to the profound decrease in serum estrogen concentration after initiation of aromatase inhibitors. Existing studies include only subjective hot flash data and describe the percentage of women reporting hot flashes, 8 levels of hot flash bother, 9 or hot flash severity/hot flash diary scores after treatment, 10<13 with little description of change over time. Therefore, we used longitudinal data from a randomized controlled trial comparing the effects of two aromatase inhibitors for the treatment of breast cancer to compare hot flash measures by (1) determining relationships between subjective and objective hot flash measures, (2) examining changes in subjective and objective hot flash measures over time, and (3) evaluating predictors of change in hot flashes.
METHODS

Sample and setting
Participants were recruited for a multicenter randomized clinical trial designed to study the effects of two aromatase inhibitors, exemestane or letrozole, on surrogate markers of response to antiestrogen therapy and to correlate these effects with germ-line genetic variants in candidate genes involved in estrogen metabolism and signaling. Participants were recruited from clinics at the Indiana University Melvin and Bren Simon Cancer Center including Wishard Memorial Hospital, the University of Michigan Comprehensive Cancer Center, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. All procedures were approved by three levels of review: each site's local institutional review board, cancer center scientific review committees, and General Clinical Research Center advisory committees. Women were eligible if they (1) were postmenopausal, (2) had histologically proven ductal carcinoma in situ (stage 0) or stage I-III invasive carcinoma of the breast that was estrogen receptorY and/or progesterone receptorYpositive, (3) had completed any recommended adjuvant chemotherapy, (4) were considering treatment with an aromatase inhibitor as initial adjuvant hormonal treatment or following adjuvant tamoxifen, and (5) had an Eastern Cooperative Oncology Group performance status of 0 to 2. Eligible and interested participants provided a written informed consent and authorization for release of health information.
Study procedures
Study visits, which included hot flash assessment, were completed at baseline (before the start of aromatase inhibitor therapy) and 1, 3, 6, and 12 months after starting aromatase inhibitor therapy. Because this trial is still accruing participants, not all participants enrolled had data at all available time points. They were instructed to wear the monitor for a total of 36 hours. However, not all files had a total of 36 hours of data. To maximize the use of the available data, participants were included in the analyses if they had at least 24 hours of completed diary and monitor hot flash data from baseline, 1, 3, and 6 months (n = 135).
Trained study personnel instructed participants on the use and care of the Biolog hot flash monitor and connected each participant to the monitor at the time of her clinic visit. Once the monitoring session was completed, participants followed written instructions for turning off and returning the monitor via prepaid postal mail to the study site. Each site downloaded the hot flash data from the monitors and cleaned and prepared the monitors for the subsequent participant. Downloaded data were sent via e-mail to a central laboratory at Indiana University. All hot flash monitor data were analyzed at Indiana University using customized software and established procedures with trained analysts, as described previoulsy. 7,14<16
Measures
Physiological hot flash frequency was assessed using sternal skin conductance monitoring (model 3991 SCL; UFI, Morro Bay, CA). 7,15<17 Skin conductance was monitored using single-use sensors (UFI) and a 0.5-constant voltage circuit built into the front end of a single-channel Biolog ambulatory recorder (model 7-day 3991 SCL; UFI). The electrodes were 1.5 cm in diameter and filled with 0.05 M potassium chloride Velvachol/glycol gel. Electrodes were attached 1.5 in. below the collarbones and 2 in. on either side of the sternal midline, which measure sweat gland activity, an indicator of sympathetic activation. 6 Using established scoring procedures, 1 it is possible to differentiate a hot flash from exercise and other sweating episodes. Because the electrodes are placed on the sternum, it is not a good indicator of general sympathetic activity owing to stress, fear, or anxiety as is typically measured using palmar skin conductance. The monitor is a solidstate device containing a microprocessor and 4 MB of memory powered by a 9-V battery. It measures 1.3 Â 2.8 Â 5 in. and weighs 8 oz. This machine is programmed to sample 12-bit skin conductance data once per second. It is placed in a bag and worn around the waist or across the shoulders. An event button on the monitor can be pressed by participants to signal the subjective perception of a hot flash. This event button time-stamps the sternal skin conductance data and is used to help interpret the data during data analysis. At the end of the monitoring session, the monitor is connected to a personal computer to download data and determine hot flash frequency. An objective hot flash was defined as each discrete increase of 2 Kmho or more in sternal skin conductance occurring within a 30-second period. The time between subsequent hot flashes measured by the monitor is 15 minutes. Once a hot flash is counted, another hot flash is not counted until 15 minutes had elapsed. This has been the standard in prior published studies. 1 The total number of objective hot flashes was summed for each monitoring session. Scoring was completed by trained raters, with interrater reliability exceeding 95%.
Self-reported hot flash frequency was assessed using written diaries and the electronic event button during each monitoring session. Self-reported intensity and bother were also assessed with diaries. When a participant experienced a hot flash, she pushed two red buttons on the hot flash monitor, wrote down the time of the hot flash, and rated intensity and bother in a paper diary (0 = not at all and 10 = extremely severe or 10 = extremely bothersome). 7, 18, 19 Intensity and bother of subjective hot flash frequency were individually summed for a total score at each time point.
Statistical analysis
Data analyses were performed using the Statistical Package for the Social Sciences (version 15.0; SPSS Inc., Chicago, IL) and Statistical Analysis Software (SAS 8.2 System for Windows; SAS Institute, Cary, NC). Demographic variables and hot flash outcomes were evaluated using descriptive and frequency statistics. Data were evaluated for completeness for diary and monitor sessions for all four time points (baseline, 1, 3, and 6 mo). Participants were included in the analyses if they provided both objective and self-reported hot flash data at the four time points. Hot flash monitor files were considered complete if recording sessions contained at least 24 hours of data. Missing data were found to be randomly distributed by participant and time point. Objective and selfreported hot flash frequency outcomes were standardized to 24-hour time periods to reduce missingness.
To determine the relationships between subjective and objective hot flash measures, we compared hot flash measures in four separate analyses. We hypothesized that there would be no significant differences between the hot flash measures. First, we examined the concordance between monitor and event button frequency at each time point through frequency statistics. We evaluated the total number of hot flashes recorded by the monitor alone, by the monitor and event button, and by the event button only. Second, we compared hot flash frequency as assessed using the monitor, diary, and event button at each time point using paired t tests. Third, using previously published methods, 1 the accuracy of each subjective measure (diary and event marker) was calculated using four indices: sensitivity, specificity, positive predictive value, and negative predictive value for the diary and event button compared with the reference standard of monitor hot flashes. 6, 7 These four indices were calculated using all available hot flashes for each week during waking hours. The binary data (hot flash/no hot flash) were clus-tered because each participant was measured continuously for at least 24 hours, with hot flashes occurring at multiple times during each weekly monitoring session. The CIs for specificity and sensitivity were computed as described by Zhou et al 20 by using the ratio estimator for the variance. 21, 22 To identify true negatives (no objective or subjective hot flash), each weekly monitoring period was divided into 96 consecutive 15-minute periods of data. The total number of true negatives for each woman at baseline was calculated as the total number of the 96 data segments that contained neither an objective flash nor a subjective flash (no diary and no event marker). For this analysis, we used only a subset of women who had baseline data that were scored using a more detailed method as previously described. 1 Because this scoring method is more time consuming, it was not used for all participants' data. Fourth, we examined Pearson's correlations between hot flash measures (monitor, diary, and event mark) at each time point.
To determine changes in subjective and objective hot flash measures over time, hot flash measures were analyzed as follows. We hypothesized that hot flashes would significantly increase over time on all measures. For the sample as a whole, repeated-measure analyses of covariance were used to determine significant differences over time in each hot flash measure controlling for baseline hot flash frequency. In addition, for each individual woman, the pattern of change in monitor hot flashes was evaluated over time, and women were classified into one of four groups: (1) To determine predictors of change, hot flashes were evaluated in two steps. It was hypothesized that body mass index (BMI), use of selective serotonin reuptake inhibitors, prior number of years on tamoxifen, or prior number of years of hormone therapy might be predictors of changes in hot flashes over time. First, linear regression was performed using covariates of BMI, use of selective serotonin reuptake inhibitors, prior number of years on tamoxifen, and prior number of years of hormone therapy. Second, we compared the characteristics of the four patterns of change in hot flash groups (described in the previous paragraph) using W 2 tests and analysis of variance. Groups were compared on BMI, number of years on tamoxifen, number of years on hormone therapy, and use of hot flash treatments.
Differences in hot flash parameters between the two aromatase inhibitors were not measured because the sample was not powered to evaluate drug effect. This will be evaluated once the full sample is obtained and the parent study is completed.
RESULTS
The 135 participants had a mean (SD) age of 59.76 (8. (92%). Randomization to aromatase inhibitor therapy was 57% letrozole and 43% exemestane. For the 48% of women who had previously taken hormone therapy, the mean (SD) time from discontinuation was 5.7 (5.6) years. For the 34% of women who had previously taken tamoxifen, the mean (SD) time since stopping was 2 (1.4) years, and 39% of them had stopped within 1 month or less of starting the aromatase inhibitor (13% of the total sample). Prior breast cancer treatments included surgery (100%), chemotherapy (49%), and radiation therapy (78%).
Comparisons between subjective and objective hot flash measures
The agreement between monitor and event button at each time point is shown in Fig. 1 . Overall, this figure shows that more hot flashes were recorded on the monitor than with subjective methods. At all time points, approximately 50% of hot flash events were recorded by the monitor only, another 20% were recorded by both monitor and event button, and 30% were recorded by the event button only (no monitor hot flash). Thus, at all time points, approximately 70% of detected hot flash events were recorded by the hot flash monitor, whereas only 50% were subjectively reported.
Mean hot flash frequency with SD bars for monitor, diary, and event button measures at each time point are shown in Fig. 2 . At baseline, there were no significant differences between measures. At 1 month, monitor hot flash frequency was significantly higher than diary (P = 0.03) and event button frequency (P = 0.02). At 3 months, monitor hot flash frequency was significantly higher than event button frequency (P = 0.04). At 6 months, both monitor and diary frequencies were significantly higher than event button (P = 0.03 and 0.04, respectively). Thus, at three of the four time points, significantly more hot flashes were recorded on the monitor compared with one or both subjective methods.
Results of the detailed scoring of the 46 participants' baseline data are shown in Table 1 and again document that the monitor captured more hot flashes compared with subjective methods. Sensitivity was low for diary and event button hot flash frequency. The upper limit of 95% CIs indicated that sensitivity rarely exceeded 29% for diary and event buttonYreported hot flash frequency. When a woman had a monitor hot flash, she was likely to record it in her diary 22% of the time, and with the event button, it was 25% of the time. Specificity was high for both diary and event button hot flash frequencies. Using the lower limit of the 95% CI, specificity rarely fell below 97.7%. The positive predictive value was moderate (41%-44%), and the negative predictive value was high (95%). Subsequent t tests indicated that hot flashes that were reported with the event button but not confirmed on the monitor (false positives) were significantly more intense (mean, 3.61 vs. 2.98) and more bothersome (mean, 2.90 vs. 1.99) than were hot flashes that were reported and confirmed on the monitor (true positives; P = 0.03).
Pearson's correlations between all hot flash measures at each time point are shown in Tables 2 and 3 . Consistent with the previous analyses, monitor frequency was moderately correlated with subjective diary and event button frequency (0.35 G r G 0.56). The strength of the relationship seemed to decrease over time. Subjective diary and event button frequencies were highly correlated with each other (0.90 G r G 0.97) and with hot flash intensity and bother (0.69 G r G 0.92). Monitor frequency was weakly to moderately correlated with subjective intensity and bother (0.28 G r G 0.42). In addition, subjective intensity and bother were highly correlated with each other (0.94 G r G 0.97).
Changes in subjective and objective hot flash measures over time
Changes over time for each hot flash frequency measure when controlling for baseline are shown in Table 4 . Monitor hot flashes did not significantly change over time. Both diary and event button frequencies changed over time, though in a At baseline, there were no significant differences between measures. At 1 month, monitor frequency was significantly higher than diary and event button frequencies. At 3 months, monitor frequency was significantly higher than event button frequency. At 6 months, monitor and diary frequencies were significantly higher than event button frequency. Note the large SD bars for each measure at each time point. dissimilar pattern. Diary hot flashes decreased significantly from 3 to 6 months by approximately one hot flash. In contrast, event button frequency significantly increased between 1 to 3 months (by approximately one hot flash) and then significantly decreased by nearly two hot flashes at 6 months. Hot flash intensity and bother over time are shown in Fig. 3 . There were no significant differences in intensity or bother over time.
When data were graphed for each individual woman (not shown), there was no consistent pattern of change in objective hot flashes over time. Using monitor hot flash frequency, 27% of participants had no change in hot flashes over time, 10% had increasing hot flashes over time, 12% had decreasing hot flashes over time, and 51% had a nonlinear change in hot flashes (eg, increase then decrease). Using diary hot flash frequency, 22% had no change in hot flashes, 7% had increasing hot flashes over time, 13% had decreasing hot flashes over time, and 58% had a nonlinear change.
Predictors of change in hot flashes
Using linear regression after controlling for baseline hot flash frequency, longer duration of prior hormone therapy predicted more monitor hot flashes at 6 months (P G 0.0001) . No significant predictors were identified for diary hot flash frequency. Because subjective diary and event button were highly correlated, predictors of event button frequency were not evaluated. Predictors of greater hot flash intensity were as follows: (1) at 1 month, higher BMI (P = 0.04) compared with lower BMI and (2) at 6 months, hot flash treatment use (antidepressant or herbal) compared with no treatment (P = 0.04). Predictors of hot flash bother were not evaluated because intensity and bother were highly correlated.
At the individual level, women with a nonlinear change in monitor hot flashes (51%) had taken tamoxifen for significantly more years compared with women showing other patterns of change in hot flashes over time (eg, compared with those whose monitor hot flashes increased over time, decreased, or stayed stable; P G 0.0001). In addition, women whose diary hot flashes increased over time had significantly higher BMI compared with other women (P G 0.0001).
DISCUSSION
The main purpose of this study was to evaluate hot flashes over time in relation to subjective and objective measures in women initiating aromatase inhibitors. This study provides the first comprehensive assessment of objective and subjective hot flashes over time after initiation of aromatase inhibitors for the treatment of breast cancer. Findings indicated dissimilarities between subjective and objective measures. More hot flashes were recorded on the monitor than with the diary or event button. Although monitor hot flash frequency and hot flash intensity and bother did not significantly change over time, diary and event button flashes significantly changed but in dissimilar patterns. Given these differences between measures, there were few consistent predictors of change in hot flashes identified.
The detailed sensitivity and specificity analyses revealed data similar to previous publications. Compared with a previous study, 1 sensitivity was slightly worse for both diary and event button, whereas specificity, positive predictive value, and negative predictive value were comparable. The agreement between objective and subjective frequency was worse compared with other studies that found 44% to 51% true positives and 56% false negatives 3,4 and compared with another study reporting lower true-positive scores (19%) and more false-negative scores (81%) in a group of Bangladeshi women. 23 In summary, these and other data suggest that women tend to report fewer hot flashes than are recorded on the hot flash monitor. However, whether these monitor onlyYdetected hot flashes are clinically relevant is unclear. Different information may be being picked up by the subjective and objective methods, but the clinical difference may not be significant. It is puzzling that subjective hot flashes reported by the event button and not confirmed by the monitor (false positive) were reported as more intense and bothersome than those reported by the event button and confirmed on the monitor (true positives). This may indicate that the monitor and self-reports are capturing different aspects of the hot flash experience and provides evidence that the perception of a hot flash is just as important to investigate in the absence of an objective marker of that hot flash.
Regardless of the measurement method used, our findings indicate that the clinical impact of aromatase inhibitors on hot flashes is minimal despite the significant drop in serum estrogen concentration that presumably occurs. Although some statistically significant changes in hot flashes were seen when we evaluated group data, these amounted to only one to two hot flashes per 24-hour monitoring period. Whether these differences represent measurement error with the diary and event button, normal variation in hot flashes, or a true change in hot flashes as a result of aromatase inhibitors remains unclear. In addition, when we evaluated data from individual participants, the pharmacological impact of aromatase inhibitors varied. Taking an aromatase inhibitor did not produce a progressive increase in hot flash frequency. Most participants demonstrated a nonlinear pattern over time of increasing/ decreasing or decreasing/increasing hot flashes. We hypothesize three explanations for this finding: (1) functional estrogen is already very low when postmenopausal women start an aromatase inhibitor, and the estrogen-sensitive concentration is above that which is brought about by an aromatase inhibitor; (2) the size of the change in estrogen levels is a main factor in the regulation of central thermoregulatory apparatus and the real concentration change seen with menopause is greater; or (3) women who have already been through menopause are less sensitive to further estrogen depletion, through some compensatory biologic mechanism involving pathways that remain unclear but could be local within the central nervous system. Given the differences between hot flash measures, it is not surprising that predictors of hot flashes were not consistent across measures. One predictor, higher BMI, has previously been shown to significantly predict increased subjective hot flash frequency in postmenopausal women. 24 A randomized, controlled study of raloxifene indicated that the highest number of subjective hot flashes at baseline was seen in women who were fewer years postmenopausal, who had had a surgical menopause, and who had received previous estrogen or estrogen/progestin therapy. 25 However, these variables did not consistently predict hot flashes over time after initiation of raloxifene.
Limitations of this study included a lack of racial diversity and heterogeneity on other factors such as prior use of tamoxifen, prior use of hormone therapy, postmenopausal time, and varied prior cancer treatments. Prior tamoxifen use within 4 weeks of starting an aromatase inhibitor (13% of the sample) could explain why some women did not experience a significant increase in hot flashes from baseline. In addition, concurrent prescriptions and over-the-counter medications (other than hot flash treatments) were not evaluated to determine their role in hot flashes. The burden of asking women to write in a paper diary and push an event button could have reduced concordance for either one of these measures with the objective hot flash measure. Participants were not asked to document whether hot flashes occurred during sleep or wake. A large number of nighttime (sleeping) hot flashes could have contributed to the low sensitivity findings. In addition, analyzing a 24-hour time frame for objective hot flash monitoring could be considered limited because hot flash frequency can be variable from day to day. Lastly, because we only evaluated postmenopausal women, these results cannot be generalized to women experiencing hot flashes in perimenopause as a result of processes other than a medication. 25 
CONCLUSIONS
Future researchers should consider using only one subjective measure of hot flash frequency, documentation of sleep and wake times, and a measure of either intensity or bother. Although this analysis did not examine genetic polymorphisms in drug-metabolizing enzymes as a determinant of hot flashes, future analyses are planned and will be performed after all participants have been enrolled and assessed over time and laboratory data are processed. 
